Abstract:Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of cancer with a 5-year survival rate of less than 13% due to the lack of effective diagnostic/therapeutic modalities. Paclitaxel (PTX) has been tested in pancreatic cancer (PanCa) therapy with marginally better clinical outcomes, but remains limited by its poor hemocompatibility, biodistribution, and intracellular accumulation in tumor cells. Gemcitabine (GEM) is the most effective therapy for PanCa. However, it shows only a marginal survival benefit of 6 months. The poor therapy response is attributed to high desmoplasia, unfavorable tumor microenvironment (TME), and excessive recruitment of immune suppressive cells. We have recently engineered a multi-layered Pluronic F127 and polyvinyl alcohol stabilized and poly-L-lysine coated paclitaxel loaded poly(lactic-co-glycolic acid) nanoparticle formulation (PPNPs), which effectively inhibits pancreatic tumor. In this study, we demonstrate that PPNPs effectively sensitize tumor cells to GEM via attenuation of tumor desmoplasia. Our findings also show that PPNPs synergize GEM therapy response in cell lines and in vivo mouse models. Mechanistically, PPNPs target the TME via inhibition of the sonic hedgehog (SHH) pathway and other oncogenic signaling axis that inhibits bidirectional tumor-stromal cell interaction as determined by qPCR and Western blot analyses. In addition, PPNPs effectively target tumor-associated macrophages (TAM) by repolarizing M2 into M1 phenotype via inhibiting expression of M2 markers and an increase in M1 markers in mouse macrophage cell line RAW264.7. M2 polarization of RAW264.7 cells were induced by culture with IL-4 (20 ng/mL) in the presence of PPNPs or vehicle control. Furthermore, PPNPs effectively increase phagocytic capacity in murine macrophages as determined by phagocytosis assay (Vybrant Phagocytosis Assay Kit). In conclusion, we observed that our novel PPNP nano formulation effectively targets TME, and facilitates GEM uptake by inhibiting the activation of SHH signaling and reprograming the tumor immune surveillance mechanisms. This study suggests that PPNPs have great potential for future clinical use in management of pancreatic cancer. Citation Format: Vivek K. Kashyap, Godwin P. Darkwah, Neeraj Chauhan, Mohammed Sikander, Eswara N. Ghali, Meghana Kolli, Bilal B. Hafeez, Murali M. Yallapu, Subhash C. Chauhan. Paclitaxel nanoformulation attenuates pancreatic tumor desmoplasia and alter tumor immune responses [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 486.

Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer

Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer

Enhanced Antitumor Effect of Novel Dual-Targeted Paclitaxel Liposomes

Liposomal Co-Delivery System Encapsulating Celastrol and Paclitaxel Displays Highly Enhanced Efficiency and Low Toxicity Against Pancreatic Cancer

Development And Evaluation Of A Novel Tpgs-Mediated Paclitaxel-Loaded Plga-Mpeg Nanoparticle For The Treatment Of Ovarian Cancer

Integrin-targeted paclitaxel nanoliposomes for tumor therapy

Enhanced in vivo Stability and Antitumor Efficacy of PEGylated Liposomes of Paclitaxel Palmitate Prodrug

Deoxycholic acid-modified chitooligosaccharide/mPEG-PDLLA mixed micelles loaded with paclitaxel for enhanced antitumor efficacy.

The Anti-Tumor Effects of Lung Cancer-Targeting Long-Circulating Paclitaxel-Containing Liposomes

Ultrasound-Mediated Microbubble Destruction (UMMD) Facilitates the Delivery of CA19-9 Targeted and Paclitaxel Loaded Mpeg-Plga-pll Nanoparticles in Pancreatic Cancer

Co-Delivery of Paclitaxel Prodrug, Gemcitabine and Porphine by Micelles for Pancreatic Cancer Treatment Via Chemo-Photodynamic Combination Therapy

Paclitaxel and Itraconazole Co-Encapsulated Micelle Prolongs the Survival of Spontaneous LSL-Kras(G12D/+), LSL-Trp53(R172H/+), Pdx-1-Cre Genetically Engineered Mouse Model of Pancreatic Cancer

The Anticancer Efficacy of Paclitaxel Liposomes Modified with Low-Toxicity Hydrophobic Cell-Penetrating Peptides in Breast Cancer: an in Vitro and in Vivo Evaluation

FDA-Approved Hydrogel-Mediated In Situ Sonodynamic and Chemotherapeutic Therapy for Pancreatic Cancer

Targeting Cancer-Associated Fibroblasts by Dual-Responsive Lipid-Albumin Nanoparticles to Enhance Drug Perfusion for Pancreatic Tumor Therapy.

Synergistic Cytotoxicity and Co-Autophagy Inhibition in Pancreatic Tumor Cells and Cancer Associated Fibroblasts by Dual Functional Peptide Modified Liposomes

Enhancement of Nab-Paclitaxel Antitumor Activity Through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer.

Abstract 486: Paclitaxel nanoformulation attenuates pancreatic tumor desmoplasia and alter tumor immune responses

Enhanced transcytosis and therapeutic efficacy of paclitaxel nanoparticles: Pyridylboronic acid modification and sialic acid targeting

Dehydroascorbic Acids-Modified Polymer Micelles Target Cancer Cells to Enhance Anti-Tumor Efficacy of Paclitaxel

Thermosensitive Liposomal Codelivery of HSA-Paclitaxel and HSA-Ellagic Acid Complexes for Enhanced Drug Perfusion and Efficacy Against Pancreatic Cancer.